Literatur
- 1
Heuschmann P U, Berger K, Misselwitz B. et al .
Frequency of Thrombolytic Therapy in Patients With Acute Ischemic Stroke and the Risk
of In-Hospital Mortality The German Stroke Registers Study Group.
Stroke.
2003;
34
1106-1113
- 2
The ATLANTIS, ECASS, and NINDS rt-PA Study Group Investigators .
Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS,
and NINDS rt-PA stroke trials.
Lancet.
2004;
363
768-774
- 3
The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study
Group .
Tissue plasminogen activator for acute ischemic stroke.
N Engl J Med .
1995;
333
1581-1587
- 4
Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E,
Hoxter G, Mahagne M H, Hennerici M. for the ECASS Study Group .
Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric
stroke.
JAMA.
1995;
274
1017-1025
- 5
Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E,
Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouilias P.
Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous
alteplase in acute ischaemic stroke (ECASS II).
Lancet.
1998;
352
1245-1251
- 6
Albers G W, Bares V E, Clark W M, Bell R, Verro P, Hamilton S A.
Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard
Treatment with Alteplase to Reverse Stroke (STARS) study.
JAMA.
2000;
283
1145-1150
- 7
Albers G W, Clark W M, Madden K P, Hamilton S C.
ATLANTIS trial: results for patients treated within 3 hours of stroke onset.
Stroke.
2002 Feb;
33(2)
493-495
Prof. Martin Grond
Neurologische Klinik, Kreisklinikum Siegen
Weidenauer Straße 76
57076 Siegen
